The global hemorrhagic stroke drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). Cerebral haemorrhage is another name for hemorrhagic stroke. The rapture and bleeding of cerebral blood vessels cause this disease. Intracerebral (brain) haemorrhage and subarachnoid haemorrhage are the two kinds of hemorrhagic stroke. When a fragile blood vessel inside the brain bursts, blood spills into the surrounding brain tissue, causing a hemorrhagic stroke (intracerebral hemorrhage). Hemorrhagic stroke is mainly caused by two types of compromised blood vessels that include aneurysms and arteriovenous malformations. A stroke, brain tumour, accident, or high blood pressure caused by congenital or other health issues can cause bleeding in the brain. The most common causes of hemorrhagic stroke are high blood pressure and ageing blood vessels. Hemorrhagic stroke accounts for roughly 13% of all strokes. However, it accounts for around 40% of all stroke deaths and is one of the most severe subtypes of stroke.

Over the next decade, the global hemorrhagic stroke drugs market is expected to grow with breakthrough medicines aimed to enhance stroke outcomes hitting the market. The hemorrhagic stroke treatment market's rapid expansion can be due to the introduction of novel, high-priced medicines as well as the market's significant unmet needs. Key firms, such as ZZ, are working on the development of novel medications and stem cell therapies that are more effective. In the Activase and EVT-eligible acute ischemic stroke patient population, Biotech's 3K3A-APC is meant to minimise bleeding incidence and volume. The National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH), funds the research of new hemorrhagic stroke therapies and cures. During the forecast period, this is projected to propel the global hemorrhagic stroke drugs market. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Janssen Global Services, LLC, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hemorrhagic Stroke Drugs Market by Segment

By Type 

• Antihypertensives

• Anticoagulants

• Diuretics Anticonvulsants

• Others 

By End-User 

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centers 

Global Hemorrhagic Stroke Drugs Market by Region